Keywords: USA, Prescribing trends, Prostate cancer, Johnson & Johnson, Janssen, Zytiga, Dendreon, Provenge, Sanofi, Jevtana

Zytiga overtaking Provenge in MCRPC

Article | 17 January 2012

Print This

Despite no current approval of Johnson & Johnson (NYSE: JNJ) subsidiary Janssen’s Zytiga (abiraterone) in asymptomatic/minimally symptomatic ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in